Literature DB >> 10574967

Conformational and molecular basis for induction of apoptosis by a p53 C-terminal peptide in human cancer cells.

A L Kim1, A J Raffo, P W Brandt-Rauf, M R Pincus, R Monaco, P Abarzua, R L Fine.   

Abstract

A p53-derived C-terminal peptide induced rapid apoptosis in breast cancer cell lines carrying endogenous p53 mutations or overexpressed wild-type (wt) p53 but was not toxic to nonmalignant human cell lines containing wt p53. Apoptosis occurred through a Fas/APO-1 signaling pathway involving increased extracellular levels of Fas/FasL in the absence of protein synthesis, as well as activation of a Fas/APO-1-specific protease, FLICE. The peptide activity was p53-dependent, and it had no effect in three tumor cell lines with null p53. Furthermore, the C-terminal peptide bound to p53 protein in cell extracts. Thus, p53-dependent, Fas/APO-1 mediated apoptosis can be induced in breast cancer cells with mutant p53 similar to the recently described Fas/APO-1 induced apoptosis by wt p53. However, mutant p53 without p53 peptide does not induce a Fas/APO-1 activation or apoptosis. Docking of the computed low energy conformations for the C-terminal peptide with those for a recently defined proline-rich regulatory region from the N-terminal domain of p53 suggests a unique low energy complex between the two peptide domains. The selective and rapid induction of apoptosis in cancer cells carrying p53 abnormalities may lead to a novel therapeutic modality.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10574967     DOI: 10.1074/jbc.274.49.34924

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  23 in total

1.  The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription.

Authors:  J S Steffan; A Kazantsev; O Spasic-Boskovic; M Greenwald; Y Z Zhu; H Gohler; E E Wanker; G P Bates; D E Housman; L M Thompson
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-06       Impact factor: 11.205

2.  A peptide that binds and stabilizes p53 core domain: chaperone strategy for rescue of oncogenic mutants.

Authors:  Assaf Friedler; Lars O Hansson; Dmitry B Veprintsev; Stefan M V Freund; Thomas M Rippin; Penka V Nikolova; Mark R Proctor; Stefan Rüdiger; Alan R Fersht
Journal:  Proc Natl Acad Sci U S A       Date:  2002-01-08       Impact factor: 11.205

3.  Peptides from the amino terminal mdm-2-binding domain of p53, designed from conformational analysis, are selectively cytotoxic to transformed cells.

Authors:  M Kanovsky; A Raffo; L Drew; R Rosal; T Do; F K Friedman; P Rubinstein; J Visser; R Robinson; P W Brandt-Rauf; J Michl; R L Fine; M R Pincus
Journal:  Proc Natl Acad Sci U S A       Date:  2001-10-16       Impact factor: 11.205

4.  Comparison of the protein-protein interfaces in the p53-DNA crystal structures: towards elucidation of the biological interface.

Authors:  Buyong Ma; Yongping Pan; K Gunasekaran; R Babu Venkataraghavan; Arnold J Levine; Ruth Nussinov
Journal:  Proc Natl Acad Sci U S A       Date:  2005-02-28       Impact factor: 11.205

5.  Chondroitin sulfate as a molecular portal that preferentially mediates the apoptotic killing of tumor cells by penetratin-directed mitochondria-disrupting peptides.

Authors:  Hao Yang; Shan Liu; Huawei Cai; Lin Wan; Shengfu Li; Youping Li; Jingqiu Cheng; Xiaofeng Lu
Journal:  J Biol Chem       Date:  2010-05-18       Impact factor: 5.157

6.  p53 Amino-terminus region (1-125) stabilizes and restores heat denatured p53 wild phenotype.

Authors:  Anuj Kumar Sharma; Amjad Ali; Rajan Gogna; Amir Kumar Singh; Uttam Pati
Journal:  PLoS One       Date:  2009-10-22       Impact factor: 3.240

Review 7.  Awakening guardian angels: drugging the p53 pathway.

Authors:  Christopher J Brown; Sonia Lain; Chandra S Verma; Alan R Fersht; David P Lane
Journal:  Nat Rev Cancer       Date:  2009-12       Impact factor: 60.716

8.  Therapeutic strategies for head and neck cancer based on p53 status.

Authors:  Ichiro Ota; Noritomo Okamoto; Katsunari Yane; Akihisa Takahashi; Takashi Masui; Hiroshi Hosoi; Takeo Ohnishi
Journal:  Exp Ther Med       Date:  2012-02-03       Impact factor: 2.447

9.  CP-31398 restores mutant p53 tumor suppressor function and inhibits UVB-induced skin carcinogenesis in mice.

Authors:  Xiuwei Tang; Yucui Zhu; Lydia Han; Arianna L Kim; Levy Kopelovich; David R Bickers; Mohammad Athar
Journal:  J Clin Invest       Date:  2007-12       Impact factor: 14.808

Review 10.  p53 mutations in cancer.

Authors:  Patricia A J Muller; Karen H Vousden
Journal:  Nat Cell Biol       Date:  2013-01       Impact factor: 28.824

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.